The American Association for Cancer Research’s annual conference continued Monday with Roche offering a postmortem for its ...

FDA has granted full approval to Bayer’s larotrectinib (brand name Vitrakvi), a first-in-class tropomyosin receptor kinase (TRK) inhibitor, for treatment of ... FDA and the European Commission gave ...

Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged prop-2-ynamide derivatives acting as EGFR (Exon 20 insertion [Ex20Ins] mutant) inhibitors reported to be useful for the ...

More information: Prakash Jadhav et al, Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates, Nature Communications (2025). DOI: 10.1038/s41467-025-56902-x ...